TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00310765
Drug: Placebo first followed by open label pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Look alike placebo 75 mg po BID and increase to 150 mg BID after 3 days if no improvement for 7 weeks. Open label pregabalin 150 mg BID for last 4 weeks of study.
Study: NCT00846027
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study: NCT00846027
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel was supplied as a sterile liquid in glass vials.
Study: NCT01071044
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
Study: NCT00846027
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine was supplied as a sterile liquid in glass vials.
Study: NCT03640403
Drug: Dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
Study: NCT03640403
Drug: Artesunate-amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
Study: NCT01416558
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study
Study: NCT00089544
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00058318
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
Study: NCT00089544
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03345849
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral; Tablet
Study: NCT03345849
Drug: Placebo for Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral; Tablet
Study: NCT00089544
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT01420861
Drug: GTx-758
Normalized name: GTX-758
DrugBank: GTX-758 (DB14969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two GTx 758 tablets per day
Study: NCT00227994
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
Study: NCT00227994
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
Study: NCT03674814
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
Study: NCT03674814
Drug: Relacorilant
Normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
Study: NCT02189252
Drug: Epanova
Normalized name: Epanova
DrugBank: Omega-3-carboxylic acids (DB09568)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01926652
Drug: candesartan cilexetil 32mg, amlodipine 10mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.
Study: NCT02189252
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01111513
Drug: 48-hour ropivacaine infusions
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
Study: NCT01111513
Drug: Single dose ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 20 ml of ropivacaine 0.5% pre-operation
Study: NCT04475029
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
Study: NCT02134951
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of saline solution with ketamine
Study: NCT04475029
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
Study: NCT04290572
Drug: Isotretinoin capsules
Normalized name: Isotretinoin Capsules
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jelly capsules of isotretinoin
Study: NCT01101594
Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
Study: NCT01113931
Drug: Doxycyline Hyclate tablet
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg tablet, once daily for 7 days
Study: NCT01113931
Drug: Vibramycin (doxycyline hyclate) capsule
Normalized name: doxycycline hyclate Oral Capsule [Vibramycin]
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsule, twice daily for 7 days, over-encapsulated
Study: NCT00687713
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
Study: NCT01557335
Drug: EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
Study: NCT03122158
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
Study: NCT04066725
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given ASA 81 mg orally once daily for a total of 60 days
Study: NCT04066725
Drug: Aspirin 325mg
Normalized name: ASPIRIN 325MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given ASA 325 mg orally once daily for a total of 60 days
Study: NCT03020979
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 500mg apatinib daily orally.
Study: NCT02106182
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03795194
Drug: ampicillin/clavulanate
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved antibiotic
Study: NCT00681213
Drug: Tacrolimus/MMF
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00681213
Drug: Neoral/Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00894543
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
Study: NCT01643616
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
Study: NCT01643616
Drug: Prilocaine 1%
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
Study: NCT01643616
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
Study: NCT01643616
Drug: Prilocaine 1%
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10ml Prilocaine 1% for saphenous nerve block
Study: NCT04249076
Drug: Clobetasol Propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
Study: NCT01381731
Drug: diquafosol tetrasodium ophthalmic solution 2%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opthalmic solution 2 drops in each eye QID
Study: NCT00010036
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00010036
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04563624
Drug: composite blocks
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cad cam composite blocks
Study: NCT04563624
Drug: ceramic cad cam blocks
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceramic cad cam blocks
Study: NCT00066443
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
Study: NCT00066443
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
Study: NCT00377468
Drug: Delta9-Tetrahydrocannabinol
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03140033
Drug: Misoprostol Oral Tablet
Normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
Study: NCT03140033
Drug: Ranitidine Oral Tablet
Normalized name: ranitidine Oral Tablet
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at cord clamping the patient will recieve ranitidine sublingually
Study: NCT01247324
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01247324
Drug: Ocrelizumab-matching placebo
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01247324
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01247324
Drug: Interferon beta-1a-matching placebo
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00648973
Drug: Diphenhydramine 50 mg
Normalized name: diphenhydrAMINE 50 mg oral tablet
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet
Study: NCT00648973
Drug: Diphenhydramine 25 mg
Normalized name: diphenhydrAMINE 25 mg oral tablet
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet
Study: NCT00648973
Drug: Pseudoephedrine 120 mg
Normalized name: pseudoephedrine 120 mg oral tablet, extended release
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet
Study: NCT00585052
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
Study: NCT00532142
Drug: Intravitreal Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02106845
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
Study: NCT01522794
Drug: NOX-H94
Normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single i.v. infusion
Study: NCT03002428
Drug: Teriparatide (PF708)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection
Study: NCT03002428
Drug: Teriparatide (Forteo)
Normalized name: TERIPARATIDE (FORTEO) 250MCG/ML (600MCG) INJ,PEN,2.4ML
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection
Study: NCT02015520
Drug: Clazakizumab
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00933712
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
Study: NCT02813369
Drug: naloxegol
Normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: non-interventional study where patients are exposed to naloxegol during normal clinical practice
Study: NCT03112135
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
Study: NCT03112135
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical TXA 1 gm diluted in 200 ml saline
Study: NCT03112135
Drug: Adrenalin
Normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical adrenaline 1 mg diluted on 200 ml saline
Study: NCT04400136
Drug: Lansoprazole oral tablets 30 mg
Normalized name: lansoprazole Disintegrating Oral Tablet
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post operative prescription
Study: NCT02106845
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily orally 160 mg (4 tablets 40 mg)
Study: NCT02098915
Drug: intravenous metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
Study: NCT00003316
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00301808
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
Study: NCT00301808
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 on day 1 of each cycle
Study: NCT00301808
Drug: Pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
Study: NCT02955056
Drug: Forsteo
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 micrograms/80 microlitres solution for injection in pre-filled pen
Study: NCT01636687
Drug: Secukinumab 150mg
Normalized name: SECUKINUMAB 150MG/ML INJ,SYR,1ML
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
Study: NCT01636687
Drug: Secukinumab 300mg
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
Study: NCT00129376
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00367627
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02949583
Drug: chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
Study: NCT01895023
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
Study: NCT01895023
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
Study: NCT01895023
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
Study: NCT04004819
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A lower dosage of rituximab for HTLV-1-associated myelopathy
Study: NCT01032798
Drug: mepivacaine
Normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
Study: NCT02999022
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
Study: NCT00453895
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50mg Sunitinib
Study: NCT04034771
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol amp
Study: NCT00906529
Drug: Levemir (Detemir) and Novolog (Aspart) Insulin
Normalized name: insulin detemir Injectable Solution [Levemir]
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
Study: NCT00547469
Drug: DDP733
Normalized name: DDP733
DrugBank: DDP733 (DB05049)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01084031
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous propofol with sevoflurane inhalation induction
Study: NCT01869946
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00362141
Drug: levetiracetam (add-on)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00034697
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes